|
|
|
|
Research from Royal Marsden Hospital has provided new data on breast cancer therapy
- (NewsRx.com) -- New investigation results, 'Routine prophylactic granulocyte colony stimulating factor (GCSF) is not necessary with accelerated (dose dense) paclitaxel for early breast cancer,' are detailed in a study published in...
|
|
|
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for a
Heymach JV et al.Vandetanib with paclitaxel and carboplatin (VPC) was safely administered to nonsmall-cell lung cancer (NSCLC) pts including pts with squamous cell histology and treated brain metastases. Compared with ...
|
|
|
Phase 3 Trial of Motesanib in Non-Small-Cell Lung Cancer Suspended
Phase 3 Trial of Motesanib in Non-Small-Cell Lung Cancer Suspended November 21, 2008 A phase 3 clinical trial of non-small-cell lung cancer (NSCLC) patients has been temporarily suspended after a planned safety review showed more deaths with...
|
|
|
Amgen, Takeda & Millennium provide update on phase-3 trial of motesanib in patients with NSCLC
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited, announced that enrolment in the phase-3 Monet1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and...
|
|
|
Cancer drug trial suspended by Amgen
Late-stage trial of a cancer drug is suspended by biotech drugmaker Amgen Inc.and a unit of Japanese drugmaker Takeda Pharmaceutical Co. Those patients who were on Placebo were died after taking the drug. A safety committee will...
|
|
|
Amgen, Takeda and Millennium suspend enrollment in Phase III lung cancer trial
Amgen and Millennium, the Takeda oncology company, a subsidiary of Takeda Pharmaceutical Company, have announced that enrollment in the Phase III Monet1 trial evaluating motesanib in combination with paclitaxel and carboplatin for the...
|
|
|
Phase 2 Study of IMC-1121B in First-Line Treatment of Advanced Non-Small Cell Lung Cancer Commences Patient En
- (NewsRx.com) -- (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, announced that its disease-directed Phase 2 clinical trial of IMC-1121B in combination with paclitaxel and...
|
|
|
Studies from L. Decoster and co-researchers yield new data on lung cancer therapy
- (NewsRx.com) -- A report, 'Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non...
|
|
|
Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung
THOUSAND OAKS, Calif., Nov.19 /PRNewswire-FirstCall/ -- Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating...
|
|
|
East meets West for new approach to beat cancer
Integrative oncology blends orthodox and complementary medical therapies, where appropriate.One therapy exciting global interest for cancer treatment is Chinese herbal medicine, writes MARIKA SBOROS THEREs an old saying that goes: East is...
|
|
|
[external] Amgen Suspends Trial of Cancer Drug
THOUSAND OAKS, Calif.-- Biotech drugmaker Amgen (AMGN Quote - Cramer on AMGN - Stock Picks) and a unit of Japanese drugmaker Takeda Pharmaceutical suspended enrollment in a late-stage trial of a cancer drug after patients on the drug died...
|
|
|
Amgen Suspends Trial of Cancer Drug
THOUSAND OAKS, Calif.-- Biotech drugmaker Amgen (AMGN Quote - Cramer on AMGN - Stock Picks) and a unit of Japanese drugmaker Takeda Pharmaceutical suspended enrollment in a late-stage trial of a cancer drug after patients on the drug died...
|
|
|
Amgen, Takeda suspend enrollment in a lung-cancer-drug study
News, chart, profile, more Last: Delayed quote data Add to portfolio Analyst Create alert Insider Discuss Financials Sponsored by: , , ) the Thousand Oaks, Calif., biotech major, and Takeda Pharmaceutical Co.'s (TKPHY: TKPHY News, chart,...
|
|
|
Amgen, Takeda suspend enrollment in a lung-cancer-drug study
TEL AVIV (MarketWatch) -- Amgen Inc., (AMGN:AMGNNews, chart, profile, moreLast: Delayed quote dataAnalyst Create alertInsider Discuss Financials Sponsored by:, , ) the Thousand Oaks, Calif., biotech major, and Takeda Pharmaceutical Co.'s ...
|
|
|
Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung
THOUSAND OAKS, Calif., Nov.19 /PRNewswire-FirstCall/ -- Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating...
|
|
|
Amgen suspends trial of cancer drug
Biotech drugmaker Amgen Inc.and a unit of Japanese drugmaker Takeda Pharmaceutical Co. suspended enrollment in a late-stage trial of a cancer drug after patients on the drug died more often than those on placebo. The trial tests an...
|
|
|
Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung
THOUSAND OAKS, Calif., Nov.19 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited (TSE: 4052), today announced that enrollment in the Phase 3...
|
|
|
Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung
THOUSAND OAKS, Calif., Nov.19 /PRNewswire-FirstCall/ -- Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating...
|
|
|
Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung
THOUSAND OAKS, Calif., Nov.19 /PRNewswire-FirstCall/ -- Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating...
|
|
|
Amgen suspends trial of cancer drug
THOUSAND OAKS, Calif.(AP) -- Biotech drugmaker Amgen Inc. and a unit of Japanese drugmaker Takeda Pharmaceutical Co. suspended enrollment in a late-stage trial of a cancer drug after patients on the drug died more often than those on...
|
|
|
Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung
THOUSAND OAKS, Calif., Nov.19 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN - News) and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited (TSE: 4052 - News), today announced that enrollment in...
|
|
|
Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung
coreAdsCreate('wnsz_20', 'loc', '100', 'wnsz_20', Latest News Tip: Easing hemorrhoid pain THOUSAND OAKS, Calif., Nov.19 /PRNewswire-FirstCall/ -- Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical...
|
|
|
Amgen suspends trial of cancer drug
THOUSAND OAKS, Calif.- Biotech drugmaker Amgen Inc. and a unit of Japanese drugmaker Takeda Pharmaceutical Co. suspended enrollment in a late-stage trial of a cancer drug after patients on the drug died more often than those on...
|
|
|
Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung
THOUSAND OAKS, Calif., Nov.19 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited (TSE: 4052), today announced that enrollment in the Phase 3...
|
|
|
Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung
THOUSAND OAKS, Calif., Nov.19 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited (TSE: 4052), today announced that enrollment in the Phase 3...
|
